Details for Patent: 8,858,961
✉ Email this page to a colleague
Title: | Compositions containing alpha-2-adrenergic agonist components |
Abstract: | Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose. |
Inventor(s): | Graham; Richard S. (Irvine, CA), Bakhit; Peter G. (Huntington Beach, CA), Olejnik; Orest (Coto De Caza, CA) |
Assignee: | Allergan, Inc. (Irvine, CA) |
Filing Date: | Jun 11, 2009 |
Application Number: | 12/482,783 |
Claims: | 1. A therapeutically effective aqueous ophthalmic composition for lowering intraocular pressure comprising: a solution containing 0.1% (w/v) of a compound selected from the group consisting of brimonidine, a salt of brimonidine, wherein the solution further comprises an oxy-chloro preservative and carboxymethylcellulose, wherein the composition has a pH between 7.0-8.0. 2. The composition of claim 1 which comprises about 0.1% (w/v) of brimonidine tartrate. 3. The composition of claim 1 which comprises 0.1% (w/v) of brimonidine tartrate. 4. The composition of either of claim 3 wherein the carboxymethyl cellulose enhances the solubility of brimonidine tartrate in solution. 5. The composition of claim 3 wherein the oxy-chloro component is Purite. 6. The composition of claim 3 further comprising boric acid. 7. The composition of claim 3 further comprising sodium borate. 8. The composition of claim 3 further comprising hydrochloric acid. 9. The composition of claim 8 wherein the composition has a pH of 7.4-8.0. |